FIGS · FIGS, Inc.

The thesis

FIGS, the healthcare-apparel maker, has a documented growth case, but the shares have run ahead of it: they closed at $18.00 on 13 October 2026, a 52-week high, with no company filing or release behind the move. The third-quarter report, expected around 5 November 2026, settles it by showing whether the raised 2026 outlook holds once the second quarter's $7.9 million tariff refund drops out.

The earlier note had the shares at $13.86 on 30 September 2026, below the August range. Adjusted daily closes show a 3-month gain of 74.4% and a 14-day relative strength index of 89.5 on 13 October 2026. The narrative is accelerating in price terms: the shares are at a new high with the last fundamental news dated 6 August 2026. The business facts have not changed since the earlier note.

Bullish and bearish views on FIGS, Inc.

The bull case on FIGS, Inc. (FIGS), in brief: Revenue growth is fast and documented. The bear case: The price now exceeds several targets.

Bull case

• Revenue growth is fast and documented. FIGS reported second-quarter revenue of $196.6 million on 6 August 2026, up 28.8% year over year, and raised its 2026 outlook to roughly 20% revenue growth (FIGS results release).
• Customer metrics grew with revenue. Press coverage of the 6 August 2026 report cites active customers up 13% to 3.1 million and average order value of $127. The board also raised the share-buyback authorization.
• Adjusted profit cleared expectations. MarketBeat records second-quarter earnings per share of $0.15 against a $0.07 consensus. The company reported an 18.6% adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin excluding the refund, against a full-year outlook of 14.8%–15.0%.
• Several analyst targets sit above the market. Barclays and KeyBanc each set a $20 target after the report, and BTIG raised its target to $22 from $20 on 7 August 2026. MarketBeat listed an average target of $18.71 on 23 September 2026.
• A large short position can add to buying if the shares keep rising.

Bear case

• The price now exceeds several targets. The $18.00 close of 13 October 2026 is above Goldman Sachs's $16 target (neutral, 7 August 2026), Telsey Advisory Group's $16 target (7 August 2026) and Morgan Stanley's $15 target (reiterated 14 September 2026, per Stock Analysis). It is close to the $18.71 average MarketBeat recorded on 23 September 2026; that average may have moved since.
• No new news explains the move. The company news feed for 12 October 2026 and 13 October 2026 shows only a market-movers list and a transcript of the August earnings call. A rise this large without a catalyst can reverse as quickly.
• The reported margin includes one-time refunds. FIGS attributed 780 basis points of second-quarter gross-margin improvement to tariff refunds in its 6 August 2026 release. The full-year adjusted EBITDA margin outlook of 14.8%–15.0% sits below the second quarter's 18.6%, which points to lower margins in the second half.
• Insiders have only sold. MarketBeat reported $13.2 million of insider sales over the past 12 months and no insider purchases, as of late September 2026.

Price setup

The adjusted close of $18.00 on 13 October 2026 equals the 52-week high, so the shares sit at 0.0% from it. The 3-month gain is 74.4% and the 14-day relative strength index is 89.5. Readings that high mean the shares have risen almost without pause.

On 23 September 2026, MarketBeat recorded a 50-day moving average of $12.91 and a 200-day moving average of $13.09. The current close is well above both, and both averages have since moved. The August range is the nearest prior reference: closes of $14.26 on 7 August 2026 and $14.68 on 21 August 2026. The shares have now cleared it, and a close back under $14.68 would put them inside that range again.

The next scheduled event is the third-quarter report. The shares enter it at their high, so the report is judged against a much higher price than the one the August beat produced.

Catalysts, next 30 days

• ~16 October 2026, est. — Company announcement of the third-quarter earnings date. FIGS made the equivalent announcement for the 2025 third quarter on 16 October 2025.
• ~24 October 2026, est. — Short-interest publication for the 15 October 2026 settlement. It shows whether short sellers covered during the rally, which would have added to buying, or increased their positions.
• ~5 November 2026, est. — Third-quarter 2026 results, after the market close; the company has not confirmed the date. This is the first test of roughly 20% revenue growth and the 14.8%–15.0% adjusted EBITDA margin outlook without the tariff refund.

What would change the view

The case breaks if the third-quarter report cuts the roughly 20% 2026 revenue-growth outlook or the 14.8%–15.0% adjusted EBITDA margin outlook, or if gross margin excluding tariff refunds falls short of the second quarter's trend. The price condition is a daily close below $14.68, the 21 August 2026 close and the top of the August range, which would erase the October breakout.

A case for a higher rating would need a fundamental source for the rise: a raised outlook, slower margin decline excluding refunds, or active-customer growth above the 13% reported in August. Until one appears, price is the only evidence that changed.

What it trades with

FIGS trades with US consumer-discretionary and small-cap shares, and its demand depends on healthcare employment. Slower healthcare payroll gains in the BLS monthly jobs reports would weaken that demand. Tariff policy affects its reported gross margin directly, because the second quarter included $7.9 million of refunds. Insider vesting sales and the dual-class structure, with Class B holders keeping voting control, shape the ownership picture.